Semen Analysis | Market Size, Share & Growth Report 2025-2035
The Semen Analysis Market Report is Segmented by Test Type (Sperm Count, Motility, Morphology, Volume, and Vitality), End User (Hospitals, Fertility Clinics, Diagnostic Laboratories, Research Institutes, and others), Component (Instruments, Reagents & Kits, and Software), Service Type (Routine Semen Analysis, Advanced Semen Analysis, and Sperm DNA Fragmentation).
Semen Analysis Market
Market Analysis
How the market stands today, and what is shaping it
The global semen analysis market was estimated at approximately USD 1.2 billion in 2025 and is projected to reach around USD 1.9 billion by 2035, representing a CAGR of approximately 4.70% during 2025–2035, based on Core Market Research estimates. Testing is governed by the sixth edition of the WHO laboratory manual, published in July 2021, which replaced fixed reference thresholds with decision limits and added detailed descriptions of sperm DNA fragmentation and oxidative stress testing. Growth is supported by infertility affecting about 17.5% of adults worldwide, by computer-assisted platforms that report routine and advanced parameters from a single sample, and by CLIA-waived and mail-in testing that removes the requirement for a fertility clinic visit. Expansion is constrained by the interpretive difficulty of decision limits, by persistent inter-observer variability in morphology assessment, and by the fact that normal routine parameters do not exclude elevated sperm DNA fragmentation. Supply is fragmented across instrument and software manufacturers, laboratory service networks and direct-to-consumer providers, with no published per-company share, and the cohorts are often customers of one another rather than direct rivals.
Market Dynamics
Key market dynamics and their impact on the industry landscape
Market Drivers
- The World Health Organization reported on 4 April 2023 that about 17.5% of adults, roughly one in six people, experience infertility, drawing on 133 studies covering 1990 to 2021. Because semen analysis is the first-line investigation of the male partner, prevalence of that scale converts directly into first-line diagnostic volume.
- Hamilton Thorne acquired Microptic in November 2022 for artificial-intelligence-enabled analysis software, and Sperm Class Analyzer 6.3 now reports motility, concentration, morphology, DNA fragmentation, vitality, acrosome reaction and leukocytes from one platform. Consolidating parameter families into a single system reduces the equipment a laboratory needs to offer advanced testing.
- The sixth edition of the WHO laboratory manual, published in July 2021, replaced fixed reference thresholds with decision limits derived from 3,589 fertile men across 12 countries. Instruments and software must be revalidated against that edition, which converts a published standard into a replacement and upgrade cycle for laboratories.
- Medical Electronic Systems offers the SQA-iO as a CLIA-waived analyser, and Fellow prices a mail-in analysis at USD 199 through a CLIA-certified laboratory. Removing the requirement for a high-complexity laboratory visit widens the settings in which a test can be performed and the population willing to be tested.
- Astorg completed the take-private of Hamilton Thorne on 2 December 2024 and simultaneously acquired Cook Medical's Reproductive Health business, delisting Hamilton Thorne from the Toronto Stock Exchange. Combining analysis instruments with assisted reproduction consumables creates a single commercial channel into the same fertility clinic customer.
Market Challenges
- The sixth-edition WHO manual replaced reference thresholds with decision limits and reported a distribution rather than a pass or fail cut-off. That change improves scientific accuracy but complicates interpretation, because a result no longer resolves cleanly into normal or abnormal without clinical context.
- Morphology remains the parameter least reproducible between observers, which is the underlying reason computer-assisted systems were developed. Manual assessment persists in many laboratories, so the same sample can yield different morphology results depending on where it is analysed and by whom.
- No per-company revenue share is published for this market, and the only installed-base figure identified is Medical Electronic Systems' statement of more than 3,750 analysers in over 45 countries. Buyers and suppliers therefore cannot benchmark positions, which slows procurement decisions in a fragmented supplier base.
- Semen analysis measures concentration, motility and morphology, none of which directly assess chromatin integrity. A man with normal routine parameters can still have elevated sperm DNA fragmentation, so a normal routine result does not exclude a male factor and may delay appropriate investigation.
- Direct-to-consumer testing separates the result from the clinical consultation. Fellow and Legacy analyse mail-in samples and the YO Home Sperm Test returns results in about 20 minutes, but an abnormal value delivered without counselling still requires a clinician to interpret and act upon.
Opportunities
- The 2022 Human Reproduction Update analysis found the annual decline in sperm concentration doubling from 1.16% after 1972 to 2.64% after 2000. If that trajectory continues, population-level screening rather than symptom-triggered testing could become clinically justifiable, which would change testing volume fundamentally.
- Artificial-intelligence-enabled analysis, which Hamilton Thorne acquired Microptic to obtain, has potential to address the morphology reproducibility problem that manual assessment has never solved, and could allow a level of standardisation between laboratories that trained-observer methods cannot achieve.
- Sperm DNA fragmentation is already available within the Sperm Class Analyzer platform alongside routine parameters. Broader clinical acceptance of chromatin testing for couples with normal routine results may convert an advanced test into a more routine component of the male workup.
- CLIA-waived instruments such as the SQA-iO could allow semen analysis to move into urology offices and primary care, which may capture men who would not attend a fertility clinic and would otherwise remain untested.
- The World Health Organization found lifetime infertility prevalence of 16.5% in low- and middle-income countries, close to the 17.8% in high-income countries. Markets with comparable clinical need but less established andrology laboratory capacity could support instrument placement where none currently exists.
Trends and Insights
Key market trends shaping the industry landscape
Testing Moving Outside the Fertility Clinic
High impactShort-termCLIA-waived analysers, FDA-cleared home tests returning results in about 20 minutes, and mail-in services priced at USD 199 have all become available without a fertility clinic appointment.
Insight: The addressable population expands from couples already in fertility treatment to men testing on their own initiative, which changes the buyer from a clinic procurement function to an individual consumer.
Consolidation of Analysis Platforms
Medium impactMid-termHamilton Thorne acquired Microptic in November 2022, and Astorg took Hamilton Thorne private alongside Cook Medical's Reproductive Health business on 2 December 2024.
Insight: Two established computer-assisted analysis platforms and a consumables portfolio now sit under one owner, narrowing the independent supplier base that fertility clinics can choose between.
Artificial Intelligence Applied to Morphology
Medium impactMid-termMicroptic is described as a developer of artificial-intelligence-enabled computer-assisted analysis software, and version 6.3 covers seven parameter families including morphology and DNA fragmentation.
Insight: Automation is being directed at the parameter with the worst inter-observer reproducibility, which is where standardisation gains are largest rather than where throughput gains are largest.
A Standard That Describes Rather Than Decides
High impactShort-termThe sixth-edition WHO manual, published July 2021, replaced reference thresholds with decision limits and presented the distribution of parameters across 3,589 fertile men.
Insight: Laboratories must revalidate against a framework that deliberately avoids a pass or fail line, which increases the interpretive role of the clinician and the importance of software that presents distributions clearly.
Declining Sperm Counts as a Population Signal
High impactLong-termA meta-regression of 223 studies published on 15 November 2022 found sperm concentration down 51.6% and total count down 62.3% between 1973 and 2018, with the rate of decline accelerating after 2000.
Insight: A measured population-level decline supports the case for earlier and broader male testing, which is the mechanism most likely to expand routine volume over a ten-year forecast period.
Segment Analysis
Market segmentation by test type, end user, component, service type
Sperm Count and Motility are the parameters that every supplied platform measures, and they are the two the sixth-edition WHO manual is built around. Morphology is the parameter where assessment is hardest to standardise between observers, which is the principal reason computer-assisted systems exist. Volume is measured but is the least discriminating parameter, because it is a property of the ejaculate rather than of the spermatozoa. Vitality is a confirmatory test used where motility is very low, to distinguish immotile live sperm from dead sperm, so its volume is tied to abnormal results rather than to routine throughput. No published revenue split across these five parameters was identified. The structural point is that a modern analyser reports most of them from a single sample, so they are better understood as outputs of one test than as five separately purchased tests.
Geography Analysis
Regional market analysis
North America
North America is where the regulatory pathway for semen analysis devices is most defined and where consumer access has moved furthest. Medical Electronic Systems obtained FDA clearance for the SQA-V in September 2002 and clearance K220828 in August 2023, and offers the SQA-iO as CLIA-waived, which permits automated testing outside a high-complexity laboratory. Labcorp performs laboratory semen analysis at national scale and markets an FDA-cleared rapid fertility test. The direct-to-consumer channel is concentrated here, with Fellow pricing a mail-in analysis at USD 199 through a CLIA-certified laboratory, Legacy shipping samples in transport media, and the YO Home Sperm Test marketed as FDA-cleared with results in about 20 minutes. Hamilton Thorne is headquartered in the region and was taken private by Astorg on 2 December 2024. No regional market size, revenue or growth figure for North America was identified in the sources reviewed for this report. The regional position rests on documented regulatory clearances and on commercial concentration in the direct-to-consumer channel rather than on a measured market figure.
Europe
Europe supplies much of the analytical technology used globally. Microptic operates from Barcelona and develops the Sperm Class Analyzer, which is CE marked and adapted to the sixth edition of the WHO manual, and it became part of Hamilton Thorne on 30 November 2022. That acquisition was explicitly intended to expand the group's direct sales and support platform across Europe. European laboratories were also among the reference populations underpinning the WHO manual, which drew its distribution from 3,589 fertile men across 12 countries and five continents. The regional position therefore rests on device development and standards participation rather than on a distinct regulatory driver of the kind the FDA clearance and CLIA waiver pathway provides in North America.
Asia Pacific
Asia Pacific is covered by the same WHO standard as every other region, since the sixth-edition manual drew its reference distribution from 12 countries across five continents and is the reference framework instruments are built against. The 2022 Human Reproduction Update meta-regression extended its geographic coverage beyond Europe, North America and Australia to include Asia, and found the decline in sperm concentration to be a global rather than a regional phenomenon. The World Health Organization's 2023 prevalence report found lifetime infertility of 16.5% in low- and middle-income countries against 17.8% in high-income countries, so the underlying clinical need is not materially lower here. No regional revenue, installed-base or growth figure specific to this market was identified for Asia Pacific.
Latin America
No Latin America-specific regulation, reimbursement mechanism or published market figure for semen analysis was identified. Participation runs through the same global standard as elsewhere, because the sixth-edition WHO manual is the reference framework for laboratories and for the instruments sold into them. Medical Electronic Systems reports placements in more than 45 countries and Microptic markets the Sperm Class Analyzer worldwide, but neither publishes a regional breakdown, so no share of those placements can be attributed to this region from verified sources. The World Health Organization's finding that infertility prevalence is broadly comparable across income levels indicates clinical need without indicating testing capacity, and those are different things.
Middle East & Africa
Middle East & Africa has the least published evidence of any supplied region for this market. No regional adoption figure, device clearance pathway or reimbursement arrangement specific to semen analysis was identified. Medical Electronic Systems is headquartered in Israel, which places a supplier within the region, but the company reports its installed base globally rather than regionally. The 2022 meta-regression extended coverage to Africa among other regions when concluding that the decline in sperm concentration is global, which establishes clinical relevance without establishing testing volume. Recording that no regional measurement exists is the accurate position, and no growth or share claim for this region would currently be supported.
Competitive Landscape
Key players and market positioning analysis
No per-company revenue share is published for semen analysis, and the only installed-base figure identified for any supplier is Medical Electronic Systems Ltd's statement that it has placed more than 3,750 analysers in over 45 countries. The five Major Players are therefore ranked by breadth of verified participation across the supplied Component and Service Type values, and they divide into three cohorts. The first cohort is the instrument and software suppliers. Hamilton Thorne, Inc. is the broadest participant, offering computer-assisted analysis systems and, since 30 November 2022, the Sperm Class Analyzer software developed by Microptic, S.L. of Barcelona. Microptic does not appear as a separate entry because Hamilton Thorne acquired 100% of its capital stock at an enterprise value of approximately EUR 8.1 million, so the two share one owner and one revenue stream. The group itself was taken private by Astorg on 2 December 2024, alongside Cook Medical's Reproductive Health business, and Hamilton Thorne was delisted from the Toronto Stock Exchange; Astorg is a financial owner rather than an operating competitor, so Hamilton Thorne remains the trading entity. Medical Electronic Systems Ltd competes on regulatory position and reach rather than on software depth, holding FDA clearance for the SQA-V since September 2002 and clearance K220828 from August 2023, and offering the SQA-iO as a CLIA-waived instrument. The second cohort is laboratory services, where Labcorp Holdings Inc. performs routine analysis at national scale in the United States and markets an FDA-cleared rapid fertility test. The third cohort is direct-to-consumer testing, where Fellow Health, Inc. analyses mail-in samples in a CLIA-certified laboratory at a published price of USD 199 and Legacy, Inc. ships samples in transport media. These three cohorts do not compete on equal terms. Hamilton Thorne and Medical Electronic Systems sell instruments to the laboratories that Labcorp, Fellow Health and Legacy rely on, so a consumer testing company is often a customer of the analyser manufacturers rather than a rival. Adjacent suppliers exist that are correctly absent from the Major Players list. Vitrolife AB markets SpermGrad and SpermRinse for sperm preparation, but those media prepare a sample for treatment rather than measure it, so the company does not meet the participation test for this market. The principal competitive factor is alignment with the sixth edition of the WHO manual, since an instrument that cannot report against the current standard cannot serve a clinical laboratory. Future differentiation may increasingly depend on whether artificial-intelligence-enabled morphology assessment can demonstrate reproducibility that trained-observer methods have not achieved.
Major Players
Leading companies in the market
Industry Developments
9 recorded developments
Microptic released version 6.3 of the Sperm Class Analyzer, adapted to the sixth edition of the WHO manual and covering motility, concentration, morphology, DNA fragmentation, vitality, acrosome reaction and leukocytes in one platform. A single system therefore spans routine, advanced and DNA fragmentation testing.
Direct-to-consumer semen testing established a published price point, with Fellow offering a mail-in kit at USD 199 analysed in a CLIA-certified laboratory, and Legacy shipping samples in transport media. Testing became available without a clinic appointment or a physician referral.
The YO Home Sperm Test, developed by Medical Electronic Systems, was marketed as an FDA-cleared home analysis returning results in about 20 minutes and reporting against sixth-edition WHO standards. It measures sperm concentration, motility, progressive motility and motile sperm concentration, and records a video of the sample.
Astorg completed the take-private of Hamilton Thorne and the concurrent acquisition of Cook Medical's Reproductive Health business on 2 December 2024, and Hamilton Thorne was delisted from the Toronto Stock Exchange. The transaction combined analysis instruments with assisted reproduction consumables under a single owner.
The World Health Organization published its infertility prevalence report on 4 April 2023, finding that around 17.5% of the adult population, about one in six people, experience infertility during their lifetime. The estimate drew on 133 studies selected from 12,241 records covering 1990 to 2021.
Medical Electronic Systems obtained FDA clearance K220828 in August 2023 for its sperm quality analyser line. The company's SQA-V had been cleared in September 2002, and the newer SQA-iO is offered as a CLIA-waived instrument, which allows automated semen testing outside a high-complexity laboratory.
Levine and colleagues published a meta-regression in Human Reproduction Update on 15 November 2022 covering 223 studies and 288 estimates. Sperm concentration among unselected men fell 51.6% and total sperm count fell 62.3% between 1973 and 2018, with the annual rate of decline rising from 1.16% after 1972 to 2.64% after 2000.
Hamilton Thorne closed the acquisition of Microptic, S.L. of Barcelona effective 30 November 2022, announced on 1 December 2022, at an enterprise value of approximately EUR 8.1 million. Microptic develops the artificial-intelligence-enabled Sperm Class Analyzer software, consolidating two established computer-assisted semen analysis platforms under one owner.
The World Health Organization published the sixth edition of its laboratory manual for the examination and processing of human semen in July 2021. It abandoned fixed reference thresholds in favour of decision limits, drew its reference distribution from 3,589 fertile men across 12 countries and five continents, and added detailed descriptions of sperm DNA fragmentation and seminal oxidative stress testing.
Table of Contents
13 comprehensive chapters
1.1 Market Definition
1.2 Scope of the Study
1.3 Research Objectives
2.1 Research Approach
2.2 Data Sources
2.3 Market Estimation Approach
2.4 Forecast Assumptions
2.5 Research Limitations
3.1 Market Overview
3.2 Market Size and Forecast
3.3 Key Findings
3.4 Market Structure
4.1 Market Drivers
4.2 Market Challenges
4.3 Market Opportunities
4.4 Market Trends and Insights
5.1 Market Segmentation Overview
5.2 By Test Type
5.3 By End User
5.4 By Component
5.5 By Service Type
6.1 North America
6.2 Europe
6.3 Asia Pacific
6.4 Latin America
6.5 Middle East & Africa
6.6 Regional Market Comparison
7.1 Industry Developments
7.2 Industry Timeline
8.1 Market Structure and Competitive Positioning
8.2 Major Players
8.3 Strategic Developments
8.4 Key Competitive Factors
9.1 Hamilton Thorne, Inc.
9.2 Medical Electronic Systems Ltd
9.3 Labcorp Holdings Inc.
9.4 Fellow Health, Inc.
9.5 Legacy, Inc.
10.1 Market Size and Growth Outlook
10.2 Regional Market Outlook
10.3 Future Market Trends
10.4 Key Risks to the Forecast
11.1 Growth Opportunities
11.2 Key Risks and Constraints
11.3 Strategic Considerations
13.1 Glossary of Terms
13.2 Abbreviations
13.3 Research References
Scope of the Report
Report coverage and methodology
Study Period
Base Year: 2025
Forecast Period: 2025 - 2035
Geographic Scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Covered
Hamilton Thorne, Inc., Medical Electronic Systems Ltd, Labcorp Holdings Inc., Fellow Health, Inc. + more
Data Sources
Primary research, industry interviews, regulatory filings, company reports
Frequently Asked Questions
Common questions about this report
Ready to Get the Full Report?
Access comprehensive market insights, detailed analysis, and strategic recommendations to make informed business decisions.